Adherence to antihypertensive drug treatment in kidney transplant recipients.

IF 1.8 4区医学 Blood Pressure Pub Date : 2021-12-01 Epub Date: 2021-11-18 DOI:10.1080/08037051.2021.2004087

Coralie M G Georges, Arnaud Devresse, Sabrina Ritscher, Pierre Wallemacq, Stefan W Toennes, Nada Kanaan, Alexandre Persu

{"title":"Adherence to antihypertensive drug treatment in kidney transplant recipients.","authors":"Coralie M G Georges, Arnaud Devresse, Sabrina Ritscher, Pierre Wallemacq, Stefan W Toennes, Nada Kanaan, Alexandre Persu","doi":"10.1080/08037051.2021.2004087","DOIUrl":null,"url":null,"abstract":"Purpose: Hypertension is a common cardiovascular co-morbidity after kidney transplantation and contributes to shortened graft and patient survival outcomes. However, by contrast with adherence to immunosuppressive drugs, adherence to antihypertensive treatment in kidney transplant recipients has been seldom explored. The aim of the current study was to assess adherence to antihypertensive drugs in kidney transplant recipients from the Cliniques Universitaires Saint-Luc and to look for demographic and clinical characteristics associated with drug adherence.Methods: Demographic and clinical data were collected from medical files in a standardised case report form. Blood pressure was measured in the sitting position after 5 min rest, using validated oscillometric devices. Drug adherence was assessed by drug dosage in urine using liquid chromatography coupled with tandem mass spectrometry.Results: Our analysis included 53 kidney transplants recipients (75% of men, mean age: 57.2 ± 12.6 years, time since kidney transplantation: 9.5 ± 7.3 years, blood pressure: 130 ± 16/78 ± 11 mmHg on 2.1 ± 1.1 antihypertensive drugs). The proportion of patients showing full drug adherence, partial drug adherence, and total non-adherence to antihypertensive drugs was 79% (N = 42), 15% (N = 8), and 6% (N = 3), respectively. Adherent patients did not differ from less or non- adherers in any of the analysed characteristics.Conclusion: The proportion of patients adhering to antihypertensive drug treatment among kidney transplant recipients appears similar to that reported for immunosuppressive drugs in renal transplanted patients (∼70%), but much higher than that observed in patients with drug-resistant hypertension (30-40%). Our results need further confirmation in a large, multicenter, prospective cohort.","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"411-415"},"PeriodicalIF":1.8000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Pressure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08037051.2021.2004087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Purpose: Hypertension is a common cardiovascular co-morbidity after kidney transplantation and contributes to shortened graft and patient survival outcomes. However, by contrast with adherence to immunosuppressive drugs, adherence to antihypertensive treatment in kidney transplant recipients has been seldom explored. The aim of the current study was to assess adherence to antihypertensive drugs in kidney transplant recipients from the Cliniques Universitaires Saint-Luc and to look for demographic and clinical characteristics associated with drug adherence.

Methods: Demographic and clinical data were collected from medical files in a standardised case report form. Blood pressure was measured in the sitting position after 5 min rest, using validated oscillometric devices. Drug adherence was assessed by drug dosage in urine using liquid chromatography coupled with tandem mass spectrometry.

Results: Our analysis included 53 kidney transplants recipients (75% of men, mean age: 57.2 ± 12.6 years, time since kidney transplantation: 9.5 ± 7.3 years, blood pressure: 130 ± 16/78 ± 11 mmHg on 2.1 ± 1.1 antihypertensive drugs). The proportion of patients showing full drug adherence, partial drug adherence, and total non-adherence to antihypertensive drugs was 79% (N = 42), 15% (N = 8), and 6% (N = 3), respectively. Adherent patients did not differ from less or non- adherers in any of the analysed characteristics.

Conclusion: The proportion of patients adhering to antihypertensive drug treatment among kidney transplant recipients appears similar to that reported for immunosuppressive drugs in renal transplanted patients (∼70%), but much higher than that observed in patients with drug-resistant hypertension (30-40%). Our results need further confirmation in a large, multicenter, prospective cohort.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肾移植受者抗高血压药物治疗的依从性。

目的:高血压是肾移植术后常见的心血管合并症，可缩短移植期和患者生存期。然而，与免疫抑制药物的依从性相比，肾移植受者抗高血压治疗的依从性很少被探索。当前研究的目的是评估坚持抗高血压药物的肾移植受者倩碧大学医疗Saint-Luc和寻找人口和临床特点与药物的依从性有关。方法:以标准化病例报告形式从医学档案中收集人口学和临床资料。休息5分钟后，使用经过验证的振荡测量装置在坐姿测量血压。采用液相色谱联用串联质谱法测定尿中药物剂量，评价药物依从性。结果:我们的分析包括53例肾移植受者(75%为男性，平均年龄:57.2±12.6岁，肾移植时间:9.5±7.3年，血压:130±16/78±11 mmHg，服用2.1±1.1种降压药)。降压药完全依从、部分依从和完全不依从的患者比例分别为79% (N = 42)、15% (N = 8)和6% (N = 3)。在分析的任何特征中，坚持治疗的患者与不坚持治疗的患者或非坚持治疗的患者没有差异。结论:肾移植受者中坚持降压药物治疗的患者比例与肾移植患者中免疫抑制药物治疗的比例相似(~ 70%)，但远高于耐药高血压患者(30-40%)。我们的结果需要在一个大型、多中心、前瞻性队列中进一步证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Blood Pressure Medicine-Cardiology and Cardiovascular Medicine

CiteScore

3.20

自引率

5.60%

发文量

期刊介绍： For outstanding coverage of the latest advances in hypertension research, turn to Blood Pressure, a primary source for authoritative and timely information on all aspects of hypertension research and management. Features include: • Physiology and pathophysiology of blood pressure regulation • Primary and secondary hypertension • Cerebrovascular and cardiovascular complications of hypertension • Detection, treatment and follow-up of hypertension • Non pharmacological and pharmacological management • Large outcome trials in hypertension.